HomeComparePROCF vs EQR

PROCF vs EQR: Dividend Comparison 2026

PROCF yields 1818.18% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PROCF wins by $4103414683.80M in total portfolio value
10 years
PROCF
PROCF
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full PROCF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — PROCF vs EQR

📍 PROCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPROCFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PROCF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PROCF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PROCF
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, PROCF beats the other by $3,147,377,270,439,699.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PROCF + EQR for your $10,000?

PROCF: 50%EQR: 50%
100% EQR50/50100% PROCF
Portfolio after 10yr
$2051707341.94M
Annual income
$1,851,398,394,380,113.20/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PROCF
No analyst data
Altman Z
0.4
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PROCF buys
0
EQR buys
0
No recent congressional trades found for PROCF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPROCFEQR
Forward yield1818.18%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$4103414683.84M$40.5K
Annual income after 10y$3,702,796,788,756,407.00$3,819.61
Total dividends collected$4074760433.31M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PROCF vs EQR ($10,000, DRIP)

YearPROCF PortfolioPROCF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$192,518$181,818.18$11,248$547.57+$181.3KPROCF
2$3,477,331$3,271,336.99$12,701$666.53+$3.46MPROCF
3$58,943,217$55,222,471.89$14,405$814.59+$58.93MPROCF
4$937,891,469$874,822,227.57$16,413$999.84+$937.88MPROCF
5$14,012,869,532$13,009,325,660.38$18,795$1,232.92+$14012.85MPROCF
6$196,647,994,247$181,654,223,846.76$21,639$1,527.95+$196647.97MPROCF
7$2,592,865,386,485$2,382,452,032,641.56$25,057$1,903.80+$2592865.36MPROCF
8$32,132,661,421,271$29,358,295,457,731.54$29,197$2,385.87+$32132661.39MPROCF
9$374,409,247,740,494$340,027,300,019,734.44$34,250$3,008.70+$374409247.71MPROCF
10$4,103,414,683,838,736$3,702,796,788,756,407.00$40,467$3,819.61+$4103414683.80MPROCF

PROCF vs EQR: Complete Analysis 2026

PROCFStock

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Full PROCF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PROCF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PROCF vs SCHDPROCF vs JEPIPROCF vs OPROCF vs KOPROCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.